Benzodiazepines | Powers Benzo Recover

About Benzodiazepines

90+ Million
Prescriptions Annually in the U.S.

10-15%
Experience Prolonged Symptoms

30 Million
Americans Use Benzos Annually

Overview: What Are Benzodiazepines?

Benzodiazepines are a class of medications that act on the brain’s inhibitory system by enhancing the effects of GABA, a neurotransmitter that helps calm neural activity. By increasing this inhibitory signaling, they can reduce anxiety, promote sleep, relax muscles, and stabilize acute neurological states such as seizures. These medications are widely prescribed and can be effective when used appropriately.

At the same time, they are not without risk, particularly when used regularly over longer periods. Dependence, tolerance, and paradoxical reactions are factors. For a smaller, but meaningful population, benzodiazepines can create profound withdrawal symptoms, leading to sensitization and neurological dysregulation.

Common Benzodiazepines

Some of the most commonly prescribed include:

Alprazolam (Xanax) – short-acting: often used for acute anxiety or panic
Clonazepam (Klonopin) – longer-acting: used for anxiety and seizure disorders
Diazepam (Valium) – long-acting: historically one of the most widely used
Lorazepam (Ativan) – short-acting: intermediate-acting, common in both outpatient and hospital settings
Temazepam (Restoril) – short-acting: typically prescribed for sleep

How They Work

Benzodiazepines do not add or increase GABA. Instead, the drug binds to specific sites on the GABA-A receptor and amplifies the effect of GABA, the brain’s primary calming neurotransmitter. This reduces overall neural excitability, which is why they can quickly relieve symptoms like anxiety, agitation, or insomnia.

Intended Use

Benzodiazepines are generally intended for short-term or intermittent use, such as:

Acute anxiety or panic episodes
Short-term insomnia
Seizure control
Muscle spasms
Situational stress

Duration, Adaptation, & Risk

Benzodiazepines are typically intended for short-term or intermittent use. Many guidelines recommend limiting regular use, often to a few weeks, because the brain can begin to adapt to its effects over time. Dependence, however, is not always predictable. Some individuals develop it relatively quickly with regular use, while others discontinue after longer-term use with fewer difficulties.

This reflects how the nervous system adapts. With repeated exposure, the brain adjusts its inhibitory and excitatory balance, which can lead to tolerance and physical dependence. There is no fixed timeline. Risk generally increases with longer duration, higher doses, and daily use, but responses vary widely. For this reason, duration is best understood as a risk continuum, not a strict cutoff.

Persistent Symptoms After Discontinuation

Some individuals report symptoms that persist beyond the initial withdrawal period after stopping benzodiazepines. This is often referred to in the literature as protracted withdrawal, though terminology in this area is still evolving. These symptoms can include anxiety, sleep disturbance, sensory sensitivity, and cognitive difficulties. Their duration and severity vary widely, and many people improve over time, while a smaller subset reports longer recovery periods.

Current evidence suggests that these experiences are related to neuroadaptation, the brain’s adjustment to prolonged exposure to a GABA-enhancing medication. During use, the nervous system alters its inhibitory and excitatory balance. When the medication is reduced or stopped, this system can become temporarily dysregulated. This dysregulation can produce a range of symptoms, some of which may persist while the nervous system gradually stabilizes. The exact timeline of recovery is not fully understood and likely differs across individuals.

Importantly, while symptoms can be intense and disruptive, they do not necessarily indicate permanent structural damage. In most cases, the brain retains the capacity to adapt and recover over time. However, it is common to see individuals whose recovery becomes prolonged or feels “stuck.” In these cases, ongoing nervous system sensitization, fear-based conditioning, and behavioral patterns often appear to play a role in maintaining symptoms beyond the initial withdrawal phase.

For these individuals, approaches that focus on nervous system regulation, gradual desensitization, and addressing fear-based conditioning can be effective in supporting recovery.

What the Research Suggests

Studies examining longer-term outcomes after discontinuation indicate that:

Some individuals experience symptoms beyond the acute withdrawal phase
In certain cases, symptoms may persist for months or longer
Severity appears to be associated with factors such as duration of use, dosage, and rate of taper

However, estimates vary widely depending on the population studied, and the exact prevalence and mechanisms remain areas of ongoing research.

Cognitive Effects: Memory, Processing, & Executive Function

Benzodiazepines are known to affect cognitive function, particularly during active use. These effects can include memory impairment, slower processing speed, and reduced executive functioning.

Memory Impairment: Benzodiazepines can interfere with the formation of new memories (anterograde amnesia), in part through their effects on hippocampal activity. During use, individuals may experience difficulty learning new information, recalling recent events, or retaining details from daily experiences.

Processing Speed: Cognitive processing may become slower, making it harder to follow conversations, perform mental calculations, or respond quickly in everyday situations.

Executive Function: Higher-level functions such as planning, organization, decision-making, and task initiation can also be affected, particularly with longer-term or higher-dose use.

Common Withdrawal & Protracted Symptoms

A range of symptoms has been reported during benzodiazepine withdrawal and recovery. These can vary widely in both type and severity.

Commonly described symptoms include:

Insomnia
Anxiety and panic
Muscle tension, pain, or spasms
Sensory sensitivity (light, sound, touch)
Tinnitus (ringing in the ears)
Cognitive difficulties (memory, focus, processing)
Depersonalization or derealization
Gastrointestinal discomfort
Tremors or internal restlessness
Headaches

Nerve Pain
Burning Skin
Obsessive Rumination
Health Anxiety
Terror or Fear
Metallic Taste
OCD Fixations
Akathisia
Monophobia
Somatic symptoms disorder

In some cases, individuals report more intense or distressing experiences, including severe agitation, perceptual disturbances, or akathisia-like symptoms. While clinical terms can sound mild, the lived experience can feel much more intense, particularly during periods of heightened nervous system sensitization. Symptom severity exists on a spectrum. Some individuals experience mild and short-lived symptoms, while others may go through more prolonged or disruptive phases before stabilizing.

Tapering & Discontinuation

Abrupt discontinuation after regular benzodiazepine use can be unsafe and is generally not recommended. A gradual, individualized taper is typically advised. However, there is no single “correct” tapering method that applies to everyone. Some individuals tolerate steady, consistent reductions, while others benefit from smaller adjustments, particularly at lower doses.

This has led to the concept of hyperbolic tapering, which reflects the idea that the body may become more sensitive to dose reductions at lower levels. For some individuals, progressively smaller reductions can improve tolerability. That said, tapering responses vary widely. The goal is not to follow a rigid formula, but to adjust the pace based on how the individual's nervous system responds, as each person differs.

People often find the best results by switching to a longer-acting, steadier benzo, such as diazepam, though that is also quite subjective. The "best" benzo is the one that works best for you. The "best" tapering method is the one that works best for you. The important thing is to be flexible and meet your nervous system where it is, because things can change with time.

Commonly Misinterpreted Symptoms

One of the more challenging aspects of benzodiazepine use and discontinuation is that withdrawal-related symptoms can sometimes be difficult to distinguish from underlying or pre-existing conditions. For example, increased anxiety, restlessness, or sleep disruption may occur during withdrawal or between doses (interdose effects). In some cases, these symptoms may be interpreted as a return of the original condition rather than a response to the medication itself.

However, doctors commonly misdiagnose withdrawal, too. What may appear to be pre-existing conditions re-emerging can absolutely be withdrawal. Doctors also commonly misdiagnose withdrawal as panic disorder, insomnia, dysautonomia, PTSD, OCD, depression, agoraphobia, bipolar disorder, or other conditions.

This is dangerous as it can lead to unncessary over medication that could create more neurological injury or dysregulation. What often looks like other mental health (or physical health) conditions usually resolve on their own as the individual tapers off the medication and stabilizes.

Benzodiazepine Harm & Risk

Benzodiazepines remain widely prescribed medications worldwide. In the United States, they account for roughly 80–100 million prescriptions annually, representing over 30 million individual users each year. While many individuals use benzodiazepines short-term, studies suggest that a meaningful minority of users continue beyond recommended durations. Estimates vary by population, but research indicates that approximately 10–25% of users may remain on benzodiazepines for months or longer, particularly with daily use.

Overdose and Mortality Risk

Benzodiazepines alone are rarely associated with fatal overdose. However, they significantly increase risk when combined with other central nervous system depressants.

In the United States, benzodiazepines are involved in ~10,000 overdose deaths annually, most commonly in combination with opioids
Co-prescription of opioids and benzodiazepines has been associated with a substantially increased risk of respiratory depression and mortality

This interaction is one of the most well-established safety concerns in benzodiazepine prescribing.

Falls and Injury in Older Adults

Among older adults, benzodiazepines are consistently associated with increased risk of injury:

Studies show approximately a 40–60% increased risk of falls
Elevated risk of hip fractures and head injuries
Worse recovery outcomes following injury, including higher rates of hospitalization and mortality

For this reason, many clinical guidelines recommend avoiding or minimizing long-term benzodiazepine use in elderly populations.

Cognitive Effects and Dementia Risk

Benzodiazepines are associated with measurable cognitive effects, particularly during active use.

In older adults, long-term use has been linked in some studies to an increased risk of cognitive decline and dementia. However:

Most evidence comes from observational studies
Causality remains uncertain
Confounding factors (e.g., underlying anxiety, sleep disorders, early cognitive decline) may influence prescribing patterns

Current consensus:

There is a signal of risk, but not definitive proof of causation.

Dependence and Long-Term Use

With ongoing use, some individuals develop physical dependence.

Risk increases with duration, dose, and daily use
Estimates of dependence vary widely depending on definition and population
Short-term, intermittent use carries lower risk compared to continuous long-term use

Importantly, not all individuals experience significant withdrawal or difficulty discontinuing, though a subset may require gradual tapering and support.

What Research Is Still Clarifying

Scientific understanding of benzodiazepines has evolved over time, with current research focusing on:

Mechanisms of tolerance and dependence
Withdrawal and protracted symptom patterns
Neurobiological adaptation during long-term use
Strategies to improve discontinuation outcomes

Some studies have observed changes in brain function or receptor activity during long-term use and withdrawal. However, the clinical significance and long-term implications of these findings remain areas of ongoing investigation.

A Balanced Perspective

Benzodiazepines are widely used and clinically valuable in specific situations. At the same time, they carry risks, particularly with prolonged or high-dose use, that warrant careful consideration. Outcomes vary widely. Many individuals use benzodiazepines without significant complications, while others may experience dependence, withdrawal, or longer recovery periods.

Understanding both the benefits and risks allows for more informed, individualized decision-making.

References

American Society of Addiction Medicine. (2025). The ASAM clinical practice guideline on benzodiazepine tapering. https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/guidelines/benzodiazepine-tapering-2025/bzd-tapering-document—final-approved-version-for-distribution-02-28-25.pdf

Bachhuber, M. A., Hennessy, S., Cunningham, C. O., & Starrels, J. L. (2016). Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. American Journal of Public Health, 106(4), 686–688. https://doi.org/10.2105/AJPH.2016.303061

Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Bégaud, B. (2014). Benzodiazepine use and risk of Alzheimer’s disease: Case-control study. BMJ, 349, g5205. https://doi.org/10.1136/bmj.g5205

Brett, J., & Murnion, B. (2015). Management of benzodiazepine misuse and dependence. Australian Prescriber, 38(5), 152–155. https://doi.org/10.18773/austprescr.2015.055

Centers for Disease Control and Prevention. (2023). Drug overdose death rates. https://www.cdc.gov/drugoverdose/deaths/index.html

Food and Drug Administration. (2020). FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class

Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., Hulse, G. K., & Adams, C. E. (2014). Benzodiazepine dependence and its treatment with low dose flumazenil. British Journal of Clinical Pharmacology, 77(2), 285–294. https://doi.org/10.1111/bcp.12119

Huang, A. R., & Mallet, L. (2012). Prescribing benzodiazepines in older adults: A review of clinical effectiveness and risks. Journal of Clinical Pharmacy and Therapeutics, 37(4), 421–431. https://doi.org/10.1111/j.1365-2710.2011.01310.x

Lader, M. (2011). Benzodiazepines revisited—Will we ever learn? Addiction, 106(12), 2086–2109. https://doi.org/10.1111/j.1360-0443.2011.03563.x

Maust, D. T., Lin, L. A., & Blow, F. C. (2019). Benzodiazepine use and misuse among adults in the United States. Psychiatric Services, 70(2), 97–106. https://doi.org/10.1176/appi.ps.201800321

National Institute on Drug Abuse. (2024). Overdose death rates. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates

National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management. https://www.nice.org.uk/guidance/ng215

Olfson, M., King, M., & Schoenbaum, M. (2015). Benzodiazepine use in the United States. JAMA Psychiatry, 72(2), 136–142. https://doi.org/10.1001/jamapsychiatry.2014.1763

Pariente, A., Dartigues, J. F., Benichou, J., Letenneur, L., Moore, N., & Fourrier-Réglat, A. (2008). Benzodiazepines and injurious falls in community dwelling elders. Drugs & Aging, 25(1), 61–70. https://doi.org/10.2165/00002512-200825010-00006

Pottie, K., Thompson, W., Davies, S., Grenier, J., Sadowski, C. A., Welch, V., Holbrook, A. M., Boyd, C., Swenson, R., Ma, A., & Farrell, B. (2018). Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Canadian Family Physician, 64(5), 339–351.

Rudolph, J. L., & Salow, M. J. (2019). The risks of benzodiazepine use in older adults. Harvard Review of Psychiatry, 27(2), 85–92. https://doi.org/10.1097/HRP.0000000000000203

Stewart, S. A. (2005). The effects of benzodiazepines on cognition. Journal of Clinical Psychiatry, 66(Suppl 2), 9–13.

Voshaar, R. C. O., Gorgels, W. J. M. J., Mol, A. J. J., Van Balkom, A. J. L. M., Van De Lisdonk, E. H., Breteler, M. H. M., & Zitman, F. G. (2006). Tapering off benzodiazepines in long-term users. British Journal of Psychiatry, 189(6), 513–518. https://doi.org/10.1192/bjp.bp.105.012179

Zhong, G., Wang, Y., Zhang, Y., Zhao, Y., & Wang, C. (2015). Association between benzodiazepine use and dementia: A meta-analysis. PLoS ONE, 10(5), e0127836. https://doi.org/10.1371/journal.pone.0127836